Applications outside oncology are speculative only until if/when bisantrene is proven to cross the blood-brain barrier.
After that is proven, they would be no more speculative than an oncology FTO indication. You've already provided a long list of CNS indications where FTO is known to play a role.
The only new information is that until June 2020 it wasn't known to anyone other than City of Hope that bisantrene is a super-potent FTO inhibitor.
Please feel free to add in another couple of USD $10 billions, with an appropriate associated probability. Sheba results are partial response in 2/2 CNS metasteses, suggesting that the blood brain barrier was crossed.
The RAC 3-Pillar Trifecta, page-184
-
- There are more pages in this discussion • 241 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.53 |
Change
-0.060(3.79%) |
Mkt cap ! $259.9M | |||
| Open | High | Low | Value | Volume |
| $1.54 | $1.56 | $1.53 | $130.2K | 84.73K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 4993 | $1.53 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.58 | 10451 | 1 |
View Market Depth
| Last trade - 16.10pm 18/10/2024 (20 minute delay) ? |
| RAC (ASX) Chart |